Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 01 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Sildenafil for Oral Suspension. This medication is intended for treating pulmonary hypertension by relaxing blood vessels in the lungs. The drug will be produced at the company's facility in Baddi, Himachal Pradesh, India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases